247 related articles for article (PubMed ID: 25209187)
1. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes.
Kanterman J; Sade-Feldman M; Biton M; Ish-Shalom E; Lasry A; Goldshtein A; Hubert A; Baniyash M
Cancer Res; 2014 Nov; 74(21):6022-35. PubMed ID: 25209187
[TBL] [Abstract][Full Text] [Related]
2. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
3. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
[TBL] [Abstract][Full Text] [Related]
4. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Dohn LH; Jensen BV; Larsen FO
Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
[No Abstract] [Full Text] [Related]
5. [Outpatient chemotherapy of an advanced or metastatic colorectal cancer].
Sato T; Kokuba Y; Ozawa H; Hatate K; Nakamura T; Onosato W; Ihara A; Watanabe M
Gan To Kagaku Ryoho; 2006 Dec; 33 Suppl 2():257-9. PubMed ID: 17469353
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.
Chang DZ; Abbruzzese JL
Clin Adv Hematol Oncol; 2005 May; 3(5):400-4. PubMed ID: 16167013
[No Abstract] [Full Text] [Related]
7. Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model.
Kim HS; Park HM; Park JS; Sohn HJ; Kim SG; Kim HJ; Oh ST; Kim TG
Vaccine; 2010 Nov; 28(49):7787-96. PubMed ID: 20883737
[TBL] [Abstract][Full Text] [Related]
8. Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
Allegra C; George T; Yothers G
J Natl Cancer Inst; 2011 Jan; 103(1):4-5. PubMed ID: 21123834
[No Abstract] [Full Text] [Related]
9. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
François E; Berdah JF; Chamorey E; Lesbats G; Teissier E; Codoul JF; Badetti JL; Hébert C; Mari V
Cancer Chemother Pharmacol; 2008 Nov; 62(6):931-6. PubMed ID: 18273618
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.
Limagne E; Euvrard R; Thibaudin M; Rébé C; Derangère V; Chevriaux A; Boidot R; Végran F; Bonnefoy N; Vincent J; Bengrine-Lefevre L; Ladoire S; Delmas D; Apetoh L; Ghiringhelli F
Cancer Res; 2016 Sep; 76(18):5241-52. PubMed ID: 27496709
[TBL] [Abstract][Full Text] [Related]
11. Evolution of systemic therapy for metastatic colorectal cancer.
Geh JI; Ma YT
Colorectal Dis; 2011 Aug; 13(8):852-4. PubMed ID: 21762349
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
13. Current status of adjuvant therapy for colorectal cancer.
O'Connell MJ
Oncology (Williston Park); 2004 May; 18(6):751-5; discussion 755-8. PubMed ID: 15214594
[TBL] [Abstract][Full Text] [Related]
14. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
15. Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
Miyazaki Y; Harada T; Akase T; Arakawa I; Inoue T
Clin Ther; 2009; 31 Pt 2():2433-41. PubMed ID: 20110051
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
19. [Role of sequential chemotherapy in the treatment of metastatic colorectal cancer].
Tassinari D; Tamburini E; Carloni F; Nicoletti S; Ravaioli A
Recenti Prog Med; 2009 Feb; 100(2):73-9. PubMed ID: 19350798
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
Masi G; Vasile E; Loupakis F; Cupini S; Fornaro L; Baldi G; Salvatore L; Cremolini C; Stasi I; Brunetti I; Fabbri MA; Puglisi M; Trenta P; Granetto C; Chiara S; Fioretto L; Allegrini G; Crinò L; Andreuccetti M; Falcone A
J Natl Cancer Inst; 2011 Jan; 103(1):21-30. PubMed ID: 21123833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]